4D Lifetec from Cham in the canton of Zug, a pioneer in the field of early cancer detection, has banked 23.3 million Swiss francs as part of a share and investment deal with Xlife Sciences. In return, Xlife Sciences, an investment firm with a focus on innovative healthcare solutions, acquires a 20 percent stake in 4D Lifetec.
Xlife Sciences is not only making a direct cash investment in 4d Lifetec, but will also make available a software solution powered by Artificial Intelligence (AI) that has been developed specifically for 4D Lifetec, further details of which can be found in a press release. This will “massively expand” the functionality of the early cancer detection test known as 4D Lifetest.
4D Lifetec owns an immuno-oncological biomarker that has already proven its high sensitivity in cancer stages I and II in numerous clinical studies. The easy-to-use IVD-certified blood test enables unique high-throughput analysis of patient samples. Moreover, it delivers a powerful data set that can now be used to train AI through this transaction.
“Bringing these two technologies together will enable 4D Lifetec to seamlessly integrate data from diverse sources, including patient history, genetic information, and imaging, providing comprehensive decision support for oncologists”, comments Dr. Arne-Christian Faisst, co-founder and Chairman of 4D Lifetec, in the press release, adding that: “This will result definitively in more accurate early cancer diagnoses, ultimately enhancing patient care and outcomes.”
